Skip to main content
Conference Overview
Letter from the Chairs
Letter from the President
Keynotes
CME
About SNO
Browse Content
Recorded (from the live conference) – CME
Recorded (from the live conference) – Non CME
On Demand - CME
On Demand - Non CME
Browse Electronic Posters
Browse by Category
Browse by Number
Browse by Title
Browse by Presenter
Poster Wall
Presenter Center
Call for Abstracts
Scientific Abstracts
Exhibit & Support
Virtual Exhibit Hall
Login required
Exhibit Logo Wall
Login required
Sponsors
Login required
Exhibit & Support
Exhibit Information
Support Information
ISS Information
Exhibit & Support Prospectus
Product Showcase
Browse by Product Name
Browse by Company Name
Registration
CME
Recorded (from the live conference)
Pre-Recorded (On Demand)
Live
Conference App
CME Login
Login required
Toggle navigation
Login
Search
Home
Conference Overview
Letter from the Chairs
Letter from the President
Keynotes
CME
About SNO
Browse Content
Recorded (from the live conference) – CME
Recorded (from the live conference) – Non CME
On Demand - CME
On Demand - Non CME
Browse Electronic Posters
Browse by Category
Browse by Number
Browse by Title
Browse by Presenter
Poster Wall
Presenter Center
Call for Abstracts
Scientific Abstracts
Exhibit & Support
Virtual Exhibit Hall
Login required
Exhibit Logo Wall
Login required
Sponsors
Login required
Exhibit & Support
Exhibit Information
Support Information
ISS Information
Exhibit & Support Prospectus
Product Showcase
Browse by Product Name
Browse by Company Name
Registration
CME
Recorded (from the live conference)
Pre-Recorded (On Demand)
Live
Conference App
CME Login
Login required
Print Program
Tweets by 2020 SNO Meeting
Home
Browse by Poster Number
Browse by Poster Number
Browse by Poster Number
Type here to filter the list
Sort by
#
Sort by
Title
BIOM-01
Tyrosine kinase inhibitors as a treatment of symptomatic CNS metastases in oncogene-driven NSCLC.
Favorite
BIOM-02
Identifying MGMT Alterations as biomarkers of survival in lung adenocarcinoma with brain metastases
Favorite
BIOM-03
Invasive histopathology drives poor outcomes in surgically resected brain metastases
Favorite
BIOM-04
Brain Metastasis among Female Patients Diagnosed with Stage IV Breast Cancer
Favorite
BIOM-06
Clinical and prognostic significance of
KRAS
mutations for brain metastases from colorectal adenocarcinoma in the United States
Favorite
BIOM-07
Expression of androgen receptor and programmed death-ligand 1 in breast-to-brain-metastases.
Favorite
BIOM-08
TargetSelector
TM
cerebrospinal fluid (CSF) circulating tumor cells and biomarker analysis: improving sensitivity and targeted treatment options in breast and NSCLC cancer patients with CNS involvement
Favorite
BIOM-09
Multiplex analysis of CSF extracellular vesicles of intraspinal tumors
Favorite
BIOM-12
Circulating tumor DNA in adults with glioma: a systematic review and meta-analysis of biomarker sensitivity
Favorite
BIOM-16
Immunomic analysis of glioblastoma (GBM) using gene expression profiling
Favorite
BIOM-18
Tumor location is associated with CDKN2A status in IDH-mutant astrocytomas.
Favorite
BIOM-19
Metabolic alteration induced by selective knock down of GABPB1L in U251 cells
Favorite
BIOM-20
Proteomics Provides Potential Therapeutic Approaches to Glioblastoma Treatment: results from the Clinical Proteomics Tumor Analysis Consortium (CPTAC)
Favorite
BIOM-21
Correlation between ephrin-A2 expression and prognosis in patients with glioblastoma
Favorite
BIOM-22
Epidermal Growth Factor Receptor (EGFR) as a molecular determinant of glioblastoma response to dopamine receptor 2 (DRD2) inhibitors
Favorite
BIOM-23
Molecular profiling identifies novel biomarkers in a rural cohort of patients with glioblastoma
Favorite
BIOM-24
Identifying Vulnerability Signatures through Machine Learning in an Umbrella Trial for Glioblastoma
Favorite
BIOM-25
Identifying Extracellular Vesicles from Glioblastoma or Non-Neoplastic Cells via Imaging Flow Cytometry
Favorite
BIOM-26
Molecular predictors of response to selinexor in recurrent glioblastoma (GBM)
Favorite
BIOM-27
Predictive Evaluation of Quantitative Spatial Profiling of the Tumor Microenvironment by Multiplex Immunofluorescence in Recurrent Glioblastoma Treated with PD-1 Inhibitors
Favorite
BIOM-28
Identification of soluble AXL as a potential non-invasive serum biomarker for glioblastoma
Favorite
BIOM-29
pp65 CMV RNA Dendritic Cell Vaccine Causes Dynamic Lymph Node Volumetric Changes on MRI in Patients with Newly Diagnosed Glioblastoma
Favorite
BIOM-30
Decreased B cell and altered CD4+ T cell subset ratio predict favorable response to ruxolinitib in high-grade gliomas
Favorite
BIOM-31
Prognostic value of
MGMT
methylation in
IDH
mutant gliomas
Favorite
BIOM-32
High affinity fluorescent nanoparticles for detection IL13Rα2-positive extracellular vesicles and cells
Favorite
BIOM-33
Low Expression of DYNLT3 Predicts better prognosis for Female Glioblastoma Patients
Favorite
BIOM-34
Clinical, radiographic, and pathologic predictors of response to anti-PD-1 and anti-PD-L1 therapy in IDH-wildtype glioblastoma patients
Favorite
BIOM-36
The unique metabolomics based biomarkers of response to immunotherapy for glioblastoma
Favorite
BIOM-37
Initial radiographic assessment of ADC values in pediatric patients treated with DAY101 for recurrent or progressive low-grade gliomas (LGGs) harboring MEK/ERK pathway alterations
Favorite
BIOM-38
PI3K/AKT/mTOR signaling pathway activity in IDH-mutant diffuse glioma
Favorite
BIOM-40
Analysis of serum miRNA in glioblastoma patients: Targeted enrichment of extracellular vesicles enhances specificity for prognostic signature
Favorite
BIOM-41
Genetic markers correlated with progression-free survival times in glioblastoma patients undergoing treatment with Tumor Treating Fields
Favorite
BIOM-42
Association of Neutrophil-Lymphocyte Ratio with Glioma Grading and Survival
Favorite
BIOM-43
Glutamate receptor and glutamine metabolism profiling by gene expression analysis among patients with high grade glioma (HGG)
Favorite
BIOM-47
Longitudinal monitoring of plasma H3K27M in diffuse midline glioma patients treated with ONC201
Favorite
BIOM-48
PTEN
mutations predict benefit from tumor-treating fields therapy in patients with recurrent glioblastoma
Favorite
BIOM-51
Factors associated with declining sex discrepancy in meningioma with increasing tumor aggressiveness: R
etrospective review of a rural Pennsylvania cohort
Favorite
BIOM-52
A prognostic gene expression risk score for meningioma
Favorite
BIOM-53
Diffusion MR imaging derived apparent diffusion coefficient as a potential biomarker of clinical outcome in recurrent central nervous system lymphoma
Favorite
BIOM-55
DGKζ-targeted regulation of miR-34a in the proliferation and tumorigenicity of human glioblastoma
Favorite
BIOM-57
Pediatric tumor classification through genome-wide methylation profiling of extracellular vesicle DNA
Favorite
BIOM-59
TERT promoter mutation and MGMT promoter methylation-mediated sensitivity to temozolomide in IDH-wildtype glioblastoma: is there a link?
Favorite
BIOM-60
Biomarker evaluation for imipridone ONC206 reveals ClpP, ATF4, MYC, EGFR and HIF1 as key predictors of anti-cancer efficacy
Favorite
BIOM-61
Functional diagnostic testing of live-cell drug response using 3D patient derived glioblastoma spheroids on the incucyte platform
Favorite
CBIO-02
Comprehensive analysis of mechanisms and molecular targets for breast cancer leptomeningeal metastasis
Favorite
CBIO-03
ATRX loss in glioma results in epigenetic dysregulation of cell cycle phase transition
Favorite
CBIO-06
MKlp2 inhibition as a novel antimitotic for glioblastoma
Favorite
CBIO-09
Intratumoral heterogeneity of dielectric properties in glioblastoma
Favorite
CBIO-11
Novel therapy to target pr-recurrent glioma
Favorite
CBIO-13
Epigenetic deregulation of nuclear translocation - a novel mechanism for treatment resistance in glioblastoma
Favorite
CBIO-14
Elucidating the mechanism of temozolomide-induced ATR activation in MGMT-methylated glioblastoma multiforme
Favorite
CBIO-15
MDM2 inhibitor synergy with BCL-XL inhibition for p53 wild type glioblastoma
Favorite
CBIO-18
G-quadruplex stabilization targets ATRX-deficient high-grade glioma via induction of p53-independent apoptosis
Favorite
CBIO-19
Low global histone H4 acetylation levels reveal candidate quiescent cell populations in glioma and distinguish tumors by grade
Favorite
CBIO-20
Molecular mechanisms of OLIG2 transcription factor in glioblastoma
Favorite
CBIO-21
H3F3A G34R/V mutations induce chromosomal instability and promote pediatric high-grade glioma formation
Favorite
CBIO-23
Proximity-dependent biotin identification (BioID2) indicates membrane trafficking and vesicle transport as a potential novel function of extracellular signal-regulated kinase 5 (ERK5).
Favorite
COVD-02
Adapting RNA-nanoparticle vaccines from glioblastoma to SARS-CoV-2
Favorite
COVD-03
Assessing the impact of Coronavirus 19 pandemic on neuro-oncology at Guy’s Cancer Centre London
Favorite
COVD-04
Real-world perspectives: Tumor Treating Fields (TTFields) utility to optimize treatment of patients with glioblastoma (GBM) amidst COVID-19 pandemic
Favorite
COVD-08
The divided principle of justice: ethical decision-making in cancer care during the COVID-19 pandemic
Favorite
COVD-09
Investigation and Summary of Diagnosis and Treatment of Neurological Tumors During COVID-19 in China
Favorite
COVD-11
The Brain Tumor and Not for Profit and Charity Experience of Covid 19: Reacting and Adjusting to an Unprecedented Global Pandemic in the 21st Century
Favorite
COVD-13
Effects of COVID-19 pandemic on neurosurgical oncology practices at Inova Health System: An institutional experience
Favorite
COVD-14
Telemedicine Review in Neuro-Oncology:
Comparative experiential analysis for Barrow Neurological Institute and Geisinger Health during the 2020 COVID-19 pandemic
Favorite
COVD-16
The COVID-19 pandemic from a neuro-oncology perspective: strategies, protocols, and lesson learned
Favorite
COVD-17
Tumor Treating Fields for glioblastoma therapy during the COVID-19 pandemic:
Expert consensus on use and experience
Favorite
COVD-18
Potential to harness SARS-COV-2 neurotropism in the delivery of oncolytic virotherapy for the treatment of high-grade glioma
Favorite
COVD-19
Cognition, Cancer, and COVID: Delivering direct-to-home tele-neuropsychology services to neuro-oncology patients
Favorite
COVD-20
COVID-19 infection during chemotherapy for malignant glioma:
outcomes among 3 patients
Favorite
COVD-22
COVID-19+ Glioma Patient Care: Lessons from a 5-Patient Case Series
Favorite
COVD-25
The Paradoxical Effect of COVID-19 on Cancer Care, including the Neuro-Oncology Setting
Favorite
COVD-26
Telephone consultations in neuro-oncology during the COVID-19 pandemic: levels of patient satisfaction and comparison with traditional face-to-face consultations
Favorite
COVD-27
The COVID-19 pandemic and neuro-oncological patients
Favorite
COVD-29
Continuation of temozolomide chemotherapy in a glioblastoma patient after resolution of COVID-19 pneumonia
Favorite
COVD-30
A snapshot of the impact of COVID-19 on patients with nervous system tumors.
Favorite
CSIG-01
Identification of pathogenesis-relevant microRNAs in brain metastasis
Favorite
CSIG-03
Reconciling tumor heterogeneity in glioblastoma using a pathway-based approach
Favorite
CSIG-04
Role of c-Met/β1 integrin complex in the metastatic cascade
Favorite
CSIG-06
Platelet derived growth factor receptor alpha as an oncogenic driver in Glioblastoma
Favorite
CSIG-09
ATRX deficiency in glioma impacts transcriptional profiles and the immune microenvironment in vivo
Favorite
CSIG-10
Genotype – kinome guided development of precision EGFR-targeted therapeutics for glioblastoma
Favorite
CSIG-11
Targeting PD-L1 in Glioblastoma using nanoparticle-based gene editing
Favorite
CSIG-12
HDACs-Sp1-BMI1 pathway is involved in the attenuation of stress- and therapy-induced death in glioma
Favorite
CSIG-13
TRPM7 Induces Tumorigenesis and Stemness Through Notch Activation in Glioma
Favorite
CSIG-14
Combining the glioblastoma cell membrane-permeabilizing effect of tumor treating fields (TTFields) with Withaferin A (and other) chemotherapy
Favorite
CSIG-15
Innovative computational platform addresses prostaglandin e receptor 3 as the master regulator mediating resistance to tumor treating fields in glioblastoma cells
Favorite
CSIG-16
Sexual dimporhism in iron acquisition in Glioblastoma
Favorite
CSIG-17
PRMT5 inhibition sensitizes glioblastoma models to trametinib treatment
Favorite
CSIG-20
L3MBTL3 suppresses medulloblastoma tumorigenesis through modulation of the NOTCH/RBPJ signaling pathway
Favorite
CSIG-21
BAF60C/SMARCD3 regulates tumor cell dissemination in Medulloblastoma
Favorite
CSIG-22
Cancer-associated missense single nucleotide variants regulate the stability and subcellular localization of NF2/Merlin
Favorite
CTIM-01
Glioblastoma re-irradiation: impact of concomitant chemotherapy
Favorite
CTIM-02
Two ounces of prevention: A systematic review and meta-analysis of VEGF and immune check point inhibition for primary and secondary prevention of brain metastases
Favorite
CTIM-03
Phase II study of Regorafenib in Bevacizumab refractory recurrent glioblastoma
Favorite
CTIM-04
Updates for a phase 2 open-labeled study of pembrolizumab plus TTFields plus maintenance temozolomide in patients with newly diagnosed glioblastoma (2-THE-TOP)
Favorite
CTIM-07
Identification of a baseline biomarker associated with tumor responses in a Phase I/IIa trial of a therapeutic CMV vaccine against recurrent glioblastoma (GBM)
Favorite
CTIM-08
Combination of the IMA950/Poly-ICLC Multipeptide Vaccine with Pembrolizumab in Relapsing Glioblastoma Patients
Favorite
CTIM-09
Double-Blinded, Placebo Controlled Phase 2 Study of ERC1671 in Recurrent Glioblastoma: Vaccine Overall Survival in Bevacizumab Naive and Bevacizumab Resistant Patients
Favorite
CTIM-10
Phase II Study of Pembrolizumab plus SurVaxM for glioblastoma at first recurrence
Favorite
CTIM-11
Phase I/II study to evaluate the safety and clinical efficacy of atezolizumab (atezo) in combination with temozolomide (TMZ) and radiation in patients with newly diagnosed glioblastoma (GBM)
Favorite
CTIM-15
Preliminary results of a phase II study of nivolumab with hypofractionated re-radiation and bevacizumab for recurrent MGMT methylated glioblastoma
Favorite
CTIM-16
Interstitial Photodynamic Therapy with 5-ALA for Malignant Glioma Recurrences
Favorite
CTIM-17
Phase I study of the safety and immunogenicity of personalized neoantigen vaccines and Tumor Treating Fields in patients with newly diagnosed glioblastoma
Favorite
CTIM-18
Dendritic Cell Vaccination in conjunction with Adjuvant TLR-3 Agonist administration Enhances Pro-inflammatory Immune Responses and is associated with Extended Survival in Malignant Glioma Patients
Favorite
CTIM-20
Phase I Study of Ibrutinib with Radiation and Temozolomide in Patients with Newly Diagnosed Glioblastoma
Favorite
CTIM-22
Phase 1 trial of Osimertinib with stereotactic radiosurgery (SRS) inPatients with brain metastases from EGFR positive Non-Small-Cell Lung Cancer(NSCLC)
Favorite
CTIM-23
A Phase 1 Trial of D2C7-IT in Combination with Atezolizumab in Recurrent WHO Grade IV Malignant Glioma (MG)
Favorite
CTIM-24
AUTOLOGOUS CD34+ ENRICHED HEMATOPOIETIC PROGENITOR CELLS GENETICALLY MODIFIED FOR HUMAN INTERFERON-α2, ARE WELL TOLERATED & RAPIDLY ENGRAFT IN PATIENTS WITH GLIOBLASTOMA MULTIFORME (TEM-GBM_001 STUDY)
Favorite
CTIM-26
Patient-specific dendritic cell vaccine (DC-ATA) pulsed with antigens from self-renewing autologous tumor cells in the treatment of newly-diagnosed glioblastoma: a phase II trial
Favorite
CTIM-27
Phase I/II Study of Controlled IL-12 as Immunotherapy for Diffuse Intrinsic Pontine Glioma (DIPG)
Favorite
CTIM-30
Efficacy of Pembrolizumab in Patients with Pituitary Carcinoma: results from a phase II study
Favorite
CTNI-01
Effect of stereotactic radiosurgery compared to whole-brain radiotherapy for limited brain metastasis on long term cognition and quality of life: A pooled analysis of randomized clinical trials
Favorite
CTNI-02
TBCRC049: A phase II study to assess the safety and efficacy of the combination of tucatinib, trastuzumab and capecitabine for the treatment of leptomeningeal metastasis in HER2 positive breast cancer
Favorite
CTNI-04
Activity of larotrectinib in tropomyosin receptor kinase (TRK) fusion cancer patients with central nervous system (CNS) metastases
Favorite
CTNI-08
A Phase 1-2 clinical trial of EO1001, a novel irreversible pan-ErbB inhibitor with promising brain penetration
Favorite
CTNI-09
A Phase I healthy volunteer study on the relative bioavailability and food effect of capsule and granule formulations of selumetinib
Favorite
CTNI-13
Updates on clinical outcomes and tumor recurrence patterns of a human pilot study assessing efficacy of belinostat (PXD-101) combining with chemoradiation in treating glioblastoma
Favorite
CTNI-14
A 3-Arm, Phase IIa Trial of Safety & Efficacy of Olinvacimab, a Monoclonal Antibody to VEGFR2 in Patients with Recurrent Glioblastoma Multiforme with Imaging and PK/PD assessments: Final report
Favorite
CTNI-16
Feasibility pilot study of OKN-007 in combination with adjuvant Temozolomide chemoradiotherapy in patients with newly diagnosed glioblastoma
Favorite
CTNI-20
PCV chemotherapy alone is associated with better clinical course in oligodendroglioma WHO grade II
Favorite
CTNI-21
Scalp sparing radiation with concurrent temozolomide and tumor treatment fields (SPARE) for patients with newly diagnosed glioblastoma
Favorite
CTNI-22
Retrospective analysis of the combined treatment of vincristine, ACNU, carboplatin and interferon-β plus radiotherapy (VAC-feron-R)in patients with diffuse astrocytoma
Favorite
CTNI-26
Accelerator-based BNCT in rescue treatment of patients with recurrent GBM: a multicenter phase II study
Favorite
CTNI-28
A Prospective, Observational Study Evaluating the Safety and Quality of Life of Tumor Treating Fields in Chinese Glioblastoma Patients
Favorite
CTNI-32
Phase I/II Study of Temozolomide Plus Nimustine Chemotherapy for Recurrent Malignant Gliomas: Kyoto Neuro-oncology Group
Favorite
CTNI-34
Initial analysis of phase-III trial - standard chemotherapy vs. chemotherapy guided by a cancer stem cell test in recurrent glioblastoma (NCT03632135)
Favorite
CTNI-35
Survival outcome and prognostic factors in anaplastic oligodendroglioma: a single-institution study of 95 cases
Favorite
CTNI-38
Pamiparib in combination with radiation therapy and/or temozolomide in patients with newly diagnosed or recurrent/refractory glioblastoma; phase 1b/2 final analysis
Favorite
CTNI-39
Phase 1b Clinical Trial of OKN-007 in Recurrent Malignant Glioma
Favorite
CTNI-41
Phase I Study of Ruxolitinib with Radiation and Temozolomide in Patients with Newly diagnosed Grade III Gliomas and Glioblastoma
Favorite
CTNI-42
First-in-human fluorescence guided surgery of high-grade gliomas using panitumumab-IRDye800
Favorite
CTNI-43
Anlotinib combined with STUPP regimen in treating patients with newly diagnosed glioblastoma multiforme: a phase II pilot study
Favorite
CTNI-44
Interim results of Phase 2 study to evaluate PI3K/mTOR inhibitor paxalisib (GDC-0084) given to newly diagnosed glioblastoma patients with unmethylated O
6
-methylguanine-methyltransferase promoter
Favorite
CTNI-45
A phase 1b/2 clinical study of napabucasin in combination with temozolomide for adult patients with recurrent or progressed glioblastoma multiforme (GBM)
Favorite
CTNI-46
A Phase II Trial of Tumor Treating Fields (TTFields) Concomitant with Radiosurgery for the Treatment of Recurrent, Bevacizumab-naïve Glioblastoma
Favorite
CTNI-52
Phase II Study of Everolimus (Afinitor
®
) for Children with Recurrent or Progressive Ependymoma
Favorite
CTNI-53
Single arm, open-label, multicenter phase II study of the radionuclide
177
Lu-DOTATATE (Lutathera) in adults with advanced intracranial meningioma
Favorite
CTNI-54
Long-Term Use of Everolimus plus Octreotide for Recurrent Intracranial or Spinal Meningioma: A Single Institution Experience
Favorite
CTNI-56
A phase II clinical trial using accelerator-based BNCT system for refractory recurrent high-grade meningioma
Favorite
CTNI-59
First safety analysis of anaplastic meningioma patients treated with Tumor Treating Fields (TTFields)
Favorite
CTNI-61
Pilot study of repeated planned glucarpidase following high dose methotrexate (HD-MTX) in CNS Lymphoma (CNSL)
Favorite
CTNI-64
MATRix regimen for newly diagnosed primary diffuse B-cell lymphoma of the central nervous system
Favorite
CTNI-65
Combined rituximab, methotrexate, procarbazine, vincristine, and cytarabine (R-MPV-A) treatment for patients with relapsed primary CNS lymphoma
Favorite
CTNI-66
One-year follow-up data of phase I/II study of tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma
Favorite
CTNI-68
Efficacy of TTFields in Elderly Patients with Newly Diagnosed Glioblastoma (GBM) – Sub-group Analysis of the EF-14 Trial
Favorite
CTNI-69
Precision neuro-oncology treatment guided by next generation sequencing (NGS)-based comprehensive genomic profiling: real world experience in Hong Kong
Favorite
CTNI-70
Long-term Survival in Glioblastoma Patients After Tumor Treating Fields (TTFields) Therapy
Favorite
CTNI-71
TTFields in routine clinical care of newly diagnosed GBM patients in Germany – first report on the fully enrolled TIGER study population
Favorite
CTNI-72
Phase 2 study of dianhydrogalactitol (VAL-083) in patients with
MGMT
-unmethylated, bevacizumab-naïve glioblastoma in the recurrent and adjuvant setting
Favorite
CTNI-73
Overall survival of newly diagnosed glioblastoma patients treated by standard therapy in comparison to standard therapy plus tumor treating fields
Favorite
CTNI-74
Pivotal TRIDENT trial: Radiation and temozolomide +/- Tumor Treating Fields in newly diagnosed glioblastoma
Favorite
CTNI-75
A pilot clinical trial of Orotecan (Val-413), a novel oral dosage formulation of irinotecan: Implications for pediatric brain tumors
Favorite
CTNI-76
Clinical Trial of VAL-083 in Newly Diagnosed MGMT-unmethylated GBM
Favorite
CTNI-78
A pediatric and young adult Phase I dose escalation safety study of BXQ-350 for refractory solid and central nervous system tumors
Favorite
CTNI-79
PriCoTTF Trial: A phase I/II trial of TTFields prior and concomitant to radiotherapy in newly diagnosed glioblastoma
Favorite
DDRE-01
Acquired and intrinsic resistance to vemurafenib in BRAF
V600E
-driven melanoma brain metastases
Favorite
DDRE-02
Therapeutic targeting of brain metastasis with ERK inhibitor LY3214996 using a novel
in vivo
model of lung-to-brain metastasis
Favorite
DDRE-03
International preclinical drug discovery and biomarker program informing an adoptive combinatorial trial for diffuse midline gliomas
Favorite
DDRE-04
miR-149-3p inhibits the GSC phenotype and re-sensitizes therapy-resistant GBM cells
Favorite
DDRE-07
DIPG harbour alterations targetable by MEK inhibitors, with acquired resistance mechanisms overcome by combinatorial inhibition
Favorite
DDRE-09
Developing IDO-PROTACs to improve immunotherapeutic efficacy in patients with glioblastoma
Favorite
DDRE-12
PNOC001 (NCT01734512): A Phase II Study of everolimus for recurrent or progressive pediatric low-grade gliomas (pLGG)
Favorite
DDRE-14
Hemp derived extracellular vesicles (EVs): a potential anti-glioma therapy
Favorite
DDRE-15
The combination therapy of PARP inhibitor and TMZ in diffuse midline glioma harboring H3 K27M-mutant.
Favorite
DDRE-16
Synergistic tumor suppression from combination of ONC201 and epigenetic modulators EZH2 or HDAC inhibitor provides a novel treatment strategy for GBM and DMG
Favorite
DDRE-17
Initial clinical experience using osimertinib in patients with recurrent malignant gliomas with EGFR alterations
Favorite
DDRE-21
PNOC015: Phase 1 study of MTX110 delivered by Convection Enhanced Delivery (CED) in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG) previously treated with radiation therapy
Favorite
DDRE-22
Novel LonP1 Inhibitors for Targeting Glioma Stem Cells
Favorite
DDRE-23
The combination PARP inhibitor olaparib with temozolomide in an experimental glioblastoma model
Favorite
DDRE-25
Novel Temozolomide Analogs to Improve Anti-Tumor Efficacy and Overcome Resistance in Glioblastoma Multiforme
Favorite
DDRE-26
Targeting the unfolded protein response potentiates marizomib antitumor activity in glioblastoma
Favorite
DDRE-30
High-Throughput Drug Screening of FDA-Approved Antineoplastic Drugs for the Treatment of Aggressive Meningiomas
Favorite
DDRE-31
Evaluation of highly potent and selective single-molecule dual EGFR/PI3K inhibitors in adult and pediatric high-grade glioma
Favorite
DDRE-32
ABC transporters restrict the brain penetration and intracranial efficacy of anticancer agents even when blood-brain barrier integrity is lost
Favorite
DDRE-33
Molecular differentiation of imipridones ONC201 and ONC206
Favorite
DDRE-34
TRIBBLES-1 (TRIB1) pseudokinase promotes survival of GBM cells by decreasing RT/TMZ induced apoptosis
Favorite
EPCO-02
Molecular Characterization of Two Novel MPNST Subgroups Identifies Therapeutic Opportunities
Favorite
EPCO-03
Report of NTRK Fusion in a Pediatric Patient with Spinal Gangliocytoma
Favorite
EPCO-04
Genomic and epigenomic hallmarks of schwannomatosis schwannomas
Favorite
EPCO-06
Molecular determinants of evolution and prognosis among diffuse lower grade astrocytomas
Favorite
EPCO-07
Leveraging Transcriptome Sequencing and Mathematical Modeling to Investigate Glioblastoma-Macrophage Interactions
Favorite
EPCO-10
Changes in alternative splicing and associated neoantigens due to therapy
Favorite
EPCO-11
In vivo functional genomic screen identifies WISP1 as an overexpressed driver of glioblastoma
Favorite
EPCO-13
Genome-wide association study in individuals of Ashkenazi Jewish ancestry identifies novel risk loci for glioma
Favorite
EPCO-16
Lactic Acid is an Epigenetic Metabolite That Drives Glioblastoma Survival and Growth
Favorite
EPCO-21
STING promoter epigenetic silencing in glioblastoma
Favorite
EPCO-22
Identifying Neoantigens for a Personalized Mutation-derived Genomic Vaccine in Patients with Newly Diagnosed Glioblastoma
Favorite
EPCO-23
Comparative Transcriptomics to Identify Targeted Therapy Candidates in High Grade Glioma
Favorite
EPCO-24
Computational approach to identifying neuroinflammation in glioblastoma multiforme (GBM)
Favorite
EPCO-28
Spheroid study of a Glioblastoma tumor identified a subclonal mutation of
EGFR
T790M
Favorite
EPCO-30
A radiomics based regression model to predict glioblastoma cell motility
Favorite
EPCO-34
Clinical and genetic evolution of ependymoma
Favorite
EPCO-37
Using Single-Cell RNA Sequencing to Identify Cellular Heterogeneity Within Non-functioning Pituitary Adenomas
Favorite
EPCO-38
Primary CNS diffuse large B-cell lymphoma with
CIC
-rearrangement identifying from pan-cancer patients excluding sarcomas
Favorite
EPID-01
Metastatic Brain Tumors in the Central Texas Military and Veteran Population
Favorite
EPID-03
Single institutional clinical and genetic analysis of metastatic prostate cancer with and without brain metastases
Favorite
EPID-04
The single center study for brain metastases of undiagnosed primary tumor and the role of surgical removal
Favorite
EPID-05
Comparative efficacy of first-line ALK-inhibitors in ALK+ lung cancer brain metastases: A network meta-analysis
Favorite
EPID-09
Quantifying social determinants of health among glioma patients
Favorite
EPID-12
Treatment Outcomes of Midline Gliomas with H3K27 M: Our Barrow Neurological Institute Experience
Favorite
EPID-13
A retrospective analysis to study the survival characteristics of patients with first progression of Glioblastoma at the Cleveland Clinic.
Favorite
EPID-14
Racial differences and disparities in patients with gliomas: a single comprehensive cancer center experience from 2008-2020
Favorite
EPID-15
Racial and socioeconomic disparities differentially affect overall and cause-specific survival in glioblastoma
Favorite
EPID-16
Epidemiological trends for longer term GBM survivors post STUPP
Favorite
EPID-17
The relationship of hormone exposure in breast cancer and subsequent risk of high grade gliomas
Favorite
EPID-18
Glioblastoma characterization in females within rural Pennsylvania:
A single institutional retrospective review
Favorite
EPID-20
Novel Glioblastoma Population-based Histologic Stain Normalization
Favorite
EPID-21
Epidemiology of malignant gliomas in Korea using nationwide big data from 2007 to 2017
Favorite
EPID-23
A systemic review of central nervous system tumors in Africa from 1960 – 2017 and the need for a central brain tumor registry in Africa
Favorite
EPID-24
Obesity in males with meningioma: a U.S. population-based study
Favorite
EPID-25
Skull base meningiomas are associated with obesity in males
Favorite
EPID-26
Clinical and histological characterization of primary central nervous system sarcoma in pediatrics. A single institution experience in a middle-income country.
Favorite
EPID-28
The impact of Rituximab combination chemotherapy on the clinical outcomes of primary central nervous system lymphoma (PCNSL): An updated meta-analysis
Favorite
EPID-29
Causes of death for primary brain and CNS tumor patients in the United States (2001 – 2016): A Population based study
Favorite
EPID-30
Predictors Associated with Long-term Survivorship for Patients with Glioblastoma using the National Cancer Database (NCDB)
Favorite
EPID-31
Contemporary management of grade 2 and 3 glioma in Alberta and Manitoba, 2012-2016: Comparison of tolerability and outcomes across chemotherapy regimens
Favorite
EPID-33
Practice variation of steroid dosing and tapering schedules among the neuro-oncology community
Favorite
EPID-35
Clinical trial enrollment rate among adolescent and young adults with central nervous system tumor at Dana-Farber Cancer Institute (DFCI)
Favorite
EPID-36
Antidepressant drug use in glioblastoma patients: an epidemiological view
Favorite
EXTH-02
Tumor-homing Induced Neural Stem Cell Therapy Inhibits the Progression of Breast Cancer Brain Metastasis and Leptomeningeal Carcinomatosis
Favorite
EXTH-05
Non-cytotoxic radiation enhances delivery of antisense oligonucleotides and improves chemo-radiation efficacy in brain tumor xenografts
Favorite
EXTH-06
Integrated molecular profiling reveals targetable molecular abnormalities shared across multiple histologies of brain metastasis
Favorite
EXTH-07
Tumor-homing induced neural stem cells secreting a cytotoxic payload as an adjuvant treatment for non-small cell lung cancer brain metastases
Favorite
EXTH-09
Neo-adjuvant Temozolomide increases the efficacy of subsequent concurrent chemoradiation in a Transglutaminase-2 dependant manner
Favorite
EXTH-11
Patient Derived Induced Neural Stem Cells for Treatment of Glioblastoma
Favorite
EXTH-12
Inhibition of CBP/p300 histone acetylation activity enhances temozolomide activity in glioblastoma patient derived xenografts
Favorite
EXTH-16
Treatment of Three Different BRAF-V600E Positive Brain Tumors with Vemurafenib and Dabrafenib/Trametinib: A Case Series
Favorite
EXTH-19
Evaluating the anti-tumor effect of a noval therapeutic agent, magmas inhibitor, in malignant glioma
Favorite
EXTH-21
Intrainfusion Catheter Movement Facilitates Increased Infusate Volume Dispersed in Agarose Gel
Favorite
EXTH-22
The CNS Penetrating Taxane TPI 287 and the AURKA Inhibitor Alisertib Improve Survival In Vivo
Favorite
EXTH-23
Multivalent targeted cytolytic agents for glioblastoma treatment
Favorite
EXTH-24
Increasing therapeutic induced neural stem cell persistence in the glioblastoma tumor resection cavity
Favorite
EXTH-25
The CSF penetration of the procaspase-activating compound (PAC-1) in combination with temozolomide (TMZ) in a nonhuman primate CSF access model.
Favorite
EXTH-26
Secondary Structure Analysis of the EGFR pre-mRNA Transcript to Identify Targetable Regions and Optimize RNA Therapy
Favorite
EXTH-29
Inhibition of lysine-specific histone demethylase 1A (KDM1A/LSD1) sensitizes glioblastoma cells to chemo and radiation therapy
Favorite
EXTH-30
Expanding the utility of pre-clinical Contrast enhanced CT (CE-CT) for tumor detection in orthotopic GBM models using radiomics
Favorite
EXTH-31
Increasing Tumor Treating Fields (TTFields) efficacy by targeting the G2 cell cycle checkpoint with Wee1 or Chk1 inhibitors in glioblastoma cell lines
Favorite
EXTH-33
Valproic acid enhances the anti-proliferative effect of tumor-treating fields on patient-derived gliosarcoma cells
in vitro
Favorite
EXTH-35
Synergistic Effect of Targeting Thioredoxin Reductase (TRx1) and Depletion of Glutathione System (GSH) in Glioblastoma Stem Cells
Favorite
EXTH-36
Pharmaceutical Inhibition of Cyclin Dependent Kinase 4/6 (CDK4/6) in Glioblastoma
Favorite
EXTH-38
Orthogonal
in vivo
models were the sole preclinical predictor of clinical efficacy in phase 1 trials of targeted therapies for glioblastoma: results of a systematic review
Favorite
EXTH-39
Hexon swapping mitigates anti-viral immune response during brain tumor virotherapy
Favorite
EXTH-40
Therapeutically targeting de novo purine biosynthesis in diffuse intrinsic pontine glioma
Favorite
EXTH-40
Therapeutically targeting de novo purine biosynthesis in diffuse intrinsic pontine glioma
Favorite
EXTH-41
The microRNA miR-138 may be responsible for some of the effects of metabolic ketosis on malignant glioma
Favorite
EXTH-43
Generation of a B-cell-based vaccine for the treatment of glioblastoma
Favorite
EXTH-44
Development of Retroviral Replicating Vectors Encoding Sequence-Optimized Nitroreductase for Prodrug Activator Gene Therapy in Human Glioma Models.
Favorite
EXTH-44
Development of Retroviral Replicating Vectors Encoding Sequence-Optimized Nitroreductase for Prodrug Activator Gene Therapy in Human Glioma Models.
Favorite
EXTH-46
Artificial intelligence-based identification of combined vandetanib and everolimus in the treatment of
ACVR1
-mutant diffuse intrinsic pontine glioma
Favorite
EXTH-47
Precision immunotherapy vaccines for Glioblastoma using cancer immunogenomics and selective gene enrichment strategy.
Favorite
EXTH-48
BMP4 Binding Peptide Amphiphile Nanofibers for the Treatment of Pediatric High-grade Gliomas
Favorite
EXTH-49
BXQ-350 targets to the lysosome and kills glioblastoma (GBM) cells via activation of apoptotic caspases in vitro
Favorite
EXTH-50
Activation of the Mitochondrial ClpP protease is Synthetically Lethal with HDAC1/2 Inhibition in Glioblastoma Model Systems
Favorite
EXTH-51
Anti-invasive efficacy and survival benefit of the YAP-TEAD inhibitor Verteporfin in preclinical glioblastoma models
Favorite
EXTH-52
Glioblastoma-targeting autologous induced neural stem cell therapy: evaluating safety, toxicity, persistence, and transplant methods in a post-surgical canine model
Favorite
EXTH-53
A brain-penetrant microtubule-targeting agent that disrupts hallmarks of glioma tumorigenesis
Favorite
EXTH-54
Enhanced Sensitivity of Human Glioma Cells for Temozolomide (TMZ) by Combining Therapy With Heat Shock Protein 90
Favorite
EXTH-55
PET, Image-Guided HDAC Inhibition of Pediatric Diffuse Midline Glioma Improves Survival in Murine Models
Favorite
EXTH-56
Disruption of functional networks in Glioblastoma to overcome therapy resistance
Favorite
EXTH-57
Investigation of the Tumoricidal Effects of Sonodynamic Therapy in Malignant Glioblastoma Brain Tumors
Favorite
EXTH-60
Characterization of the oncolytic adenovirus Delta-24-RGD as therapeutic agent for the treatment of the pediatric embryonal brain tumors AT/RT and CNS-PNET
Favorite
EXTH-61
Combination of Disulfiram and Copper induces NPL4 aggregation, targets CD133-Nestin cells and extends survival in Medulloblastoma Group 3 Models
Favorite
EXTH-62
Preclinical efficacy of the imipridone ONC-206 against medulloblastoma
Favorite
EXTH-63
In Vitro
Drug Screening Based on
in Silico
Data Identifies New Therapeutic Agents for Aggressive Meningioma
Favorite
EXTH-65
Using methylation profiles to guide the repurposing of chemotherapies against high-risk meningiomas
Favorite
EXTH-66
NEO100 Transiently Opens Up the Blood Brain Barrier via Tight Junction Inhibition
Favorite
EXTH-69
Increased cancer cell permeability following Tumor Treating Fields (TTFields) application in vitro
Favorite
EXTH-70
CYP450 and metabolic profiling of anti-cancer imipridone ONC201
Favorite
EXTH-71
Cytostatic hypothermia for glioblastoma
Favorite
EXTH-72
Continuous infusion studies reveal the potency of elacridar to act as a pharmaco-enhancer for treatment of intracranial diseases by inhibiting ABCB1 and ABCG2 at the blood-brain barrier.
Favorite
EXTH-73
Heterogeneity in cell surface antigen and HLA Class I expression in pediatric brain tumors and its impact on T-cell immunotherapy
Favorite
EXTH-75
In vitro and in vivo efficacy of combinatorial inhibition of LSD1 and HDACs in patient derived glioblastoma stem cell models
Favorite
EXTH-76
The inovivo system: a novel preclinical tool for in vivo delivery of Tumor Treating Fields (TTFields)
Favorite
EXTH-77
ONC201 exhibits passive diffusion and broad distribution in the central nervous system
Favorite
IMMU-02
The survival outcomes associated with immune checkpoint inhibitors for non-small cell lung carcinoma patients with brain metastases in the United States
Favorite
IMMU-05
CSF metabolomics as a predictor of survival in patients with brain metastasis receiving immunotherapy
Favorite
IMMU-09
Concurrent dexamethasone limits the clinical benefit of immune checkpoint blockade in glioblastoma
Favorite
IMMU-13
Efficacy of CXCR6 blockade as a Potentiator of anti-PD-1 therapy for the treatment of Glioblastoma
Favorite
IMMU-15
Heparin inhibits the extracellular vesicle-mediated induction of immunosuppressive monocytes in glioblastoma
Favorite
IMMU-18
Interplay between
IDH1
and
ATRX
mutations govern innate immune responses in gliomas
Favorite
IMMU-19
Targeting glioblastoma immunosuppression and treatment resistance with ibrutinib in combination with stereotactic radiation and immune checkpoint blockade
Favorite
IMMU-21
The combination of Delta-24-ACT with an immune checkpoint inhibitor results in anti-glioma effect and immune memory
Favorite
IMMU-23
Clinical and immunological characterization of immune checkpoint molecule LIGHT in human gliomas
Favorite
IMMU-24
Temozolomide induced immune dysfunction requires the presence of intracranial tumors
Favorite
IMMU-25
Severe and multifaceted systemic immunosuppression caused by experimental cancers of the central nervous system requires release of non-steroid soluble mediators
Favorite
IMMU-26
Unraveling antigen presentation in central nervous system anti-tumor immunity
Favorite
IMMU-28
Induction of tertiary lymphoid structure-like T-cell clusters by delivery of a novel gene combination into an immunocompetent mouse model of glioblastoma
Favorite
IMMU-29
Lag-3 compensates Tim-3 down-regulation in a human glioblastoma model
Favorite
IMMU-32
Non-Metabolic IDO Activity Increases Complement Factor H Levels Which Enhances Immunosuppression in Human Glioblastoma
Favorite
IMMU-33
Multi-antigen recognition circuits overcome challenges of specificity, heterogeneity, and durability in T-cell therapy for glioblastoma
Favorite
IMMU-42
Dual Activation of the cGAS-STING Pathway and AIM2-induced Pyroptosis by Tumor-Treating Fields Produces Anti-Tumor Immunity in Glioblastoma
Favorite
IMMU-43
Zika virus to treat glioma: turning cold tumors hot
Favorite
IMMU-44
Pre-diagnostic eosinophil level and glioblastoma development in patients with and without atopic disease
Favorite
IMMU-45
Customized lipid nanoparticles deliver nucleic acids to immune cells in brain tumors
Favorite
IMMU-46
Lineage depleted hematopoietic stem cells potentiate immune checkpoint response to anti-PD1 and anti-CD276 in murine glioma
Favorite
IMMU-47
Protein Phosphatase 2A Inhibition in NK Cell Therapy for Treatment of Medulloblastoma
Favorite
IMMU-48
CD4+ T cells restrict medulloblastoma growth and dissemination
Favorite
IMMU-49
Predicting Patient-Specific Antigens for Medulloblastoma Immunotherapy
Favorite
IMMU-51
Neurologic Immune-Related Adverse Events Mimics, Risk Factors, and Mechanisms: CLIPPERS and Aseptic Meningitis
Favorite
IMMU-52
Immune Effector Cell Associated Neurotoxicity (ICANS) among pediatric and AYA patients:MD Anderson Cancer Center experience
Favorite
INNV-04
Congenital spinal glioblastoma with sustained response to tropomyosin receptor kinase (TRK) inhibition: a case report
Favorite
INNV-05
Tumor Treating Fields (TTFields) treatment planning for a patient with astrocytoma in the spinal cord
Favorite
INNV-06
Second generation BRAF/MEK inhibition in Anaplastic Pleomorphic Xanthroastrocytoma
Favorite
INNV-10
Effects of TTFields Usage and Duration of Usage on Cellularity and Ki67 Distributions at Autopsy
Favorite
INNV-11
Glioblastoma in the Older Person – how do we decide on treatment?
Favorite
INNV-12
A single-institution retrospective review of patients with CNS tumors who initiated a ketogenic diet
Favorite
INNV-14
Utilization of a Patient Family Advisory Council to Advance Patient-Centered Care of Brain Tumor Patients
Favorite
INNV-15
Comparison of Readiband™ actigraph and associated sleep/wake classification algorithms with patient-reported sleep quality and fatigue in glioblastoma
Favorite
INNV-16
Clinical applicability of individualized drug response profiling utilizing
ex-vivo
tissue-derived 3D cell culture assays in high-grade glioma: a single institution case series using 3D-PREDICT results
Favorite
INNV-17
Next Generation Sequencing Impacts Outcomes in Recurrent Primary Glioblastoma: A Single-Center Retrospective Analysis
Favorite
INNV-18
Recurrent Shh medulloblastoma extraneural metastases to the bone marrow without CNS involvement
Favorite
INNV-19
Anaplastic cerebellar ependymoma in an adult female presenting with tonsillar herniation successfully treated with chemotherapy: A case report
Favorite
INNV-20
Elevated intracranial pressure without hydrocephalus in patients with neurofibromatosis 2
Favorite
INNV-21
Effective regimen of high-dose methotrexate plus temozolomide for primary central nervous system lymphoma: a single-center retrospective study
Favorite
INNV-24
The experience of fatigued brain tumour patients receiving innovative lifestyle interventions: Qualitative results from the BT-LIFE Randomised Controlled Trial.
Favorite
INNV-25
Patient centered multi-disciplinary neuro-oncologic care as directed by new patient stakeholders
Favorite
INNV-27
BT-LIFE (Brain Tumours, Lifestyle Interventions, and Fatigue Evaluation): Lessons learned from running a novel multi-sectoral research trial.
Favorite
INNV-28
Temozolomide in renal dysfunction
Favorite
INNV-29
Professional Practice Model for Advanced Practitioners in Neuro Oncology
Favorite
NCMP-01
The Role of Vascular Endothelial Growth Factor Receptor Inhibitors in Preventing Cerebral Radiation Necrosis: A Retrospective Cohort Study.
Favorite
NCMP-02
Cerebrospinal fluid (CSF) predictors of developing disseminated necrotizing leukoencephalopathy in leptomeningeal carcinomatosis (LMC): A single institutional review
Favorite
NCMP-03
Intrathecal trastuzumab treatment of her-2 positive leptomeningeal breast cancer: The University of Michigan experience.
Favorite
NCMP-04
Incidence and outcomes of brain metastases in patients with extra-pulmonary neuroendocrine neoplasms
Favorite
NCMP-05
Decoding the immune system response to leptomeningeal metastasis
Favorite
NCMP-06
Metastatic Central Nervous System Disease Secondary to Burkitt Lymphoma in a Patient with Prior History of Melanoma
Favorite
NCMP-07
Treatment-induced cerebral necrosis in gliomas: The Ohio State University Comprehensive Cancer Center (OSUCCC) experience
Favorite
NCMP-08
Efficacy of antiepileptic drugs in glioma patients with epilepsy: a systematic review.
Favorite
NCMP-09
Postmortem study of organ specific toxicity in glioblastoma patients treated with a combination of temozolomide, bevacizumab and irinotecan
Favorite
NCMP-10
IDH mutation status and the development of venous thromboembolism in astrocytoma patients
Favorite
NCMP-12
Rapidly progressive neuropathies as the sole presentation of neurolymphomatosis
Favorite
NCMP-13
Leptomeningeal disease following resection of intraventricular melanoma metastasis diagnosed through circulating tumor cells
Favorite
NCMP-14
Skull Base Osteomyelitis Due to Community-Acquired Aspergillus fumigatus Mimicking Recurrent Chondrosarcoma
Favorite
NCMP-15
CNS lymphoma: the great mimicker
Favorite
NCMP-17
Mismatch repair mutations and the central nervous system: A case series of germline mutations and CNS malignancy
Favorite
NCMP-18
Neurotoxicity as a Potential Surrogate Marker for Therapeutic Response with Commercial Anti-CD19 CAR T-cell Therapy
Favorite
NCMP-19
Side Effects from Chemotherapy versus Symptoms from COVID-19 Infection
Favorite
NCMP-20
A retrospective single-center experience with nonbacterial thrombotic endocarditis and stroke - outcomes, anticoagulation strategies, and incorporation of next-generation sequencing data
Favorite
NCMP-21
Reversible motor neuron syndrome in the setting of cancer
Favorite
NCMP-22
Second malignancies following treatment for primary central nervous system tumors in pediatric patients: a single-institutional retrospective review
Favorite
NCMP-23
Pembrolizumab-associated CD8+ vasculitic mononeuritis multiplex in a patient with mesothelioma: first case report
Favorite
NCMP-26
Recognition of paraneoplastic syndromes triggered by traditional cytotoxic cancer treatment, tumor recurrence and development of second cancer.
Favorite
NCMP-27
The use of Intravenous Immunoglobulin (IVIG) during severe neurotoxicity among the recipients of Chimeric Antigen Receptor T-cells (CAR-T) therapy.
Favorite
NCMP-28
Bevacizumab associated intracerebral hemorrhage in patients with primary CNS malignancy
Favorite
NCOG-01
Stereotactic radiosurgery for brain metastases at the Guy’s Cancer Center, London: An Audit for the first 17 months
Favorite
NCOG-03
Factors Associated with Adjacent Level Tumor Progression in Patients Receiving Separation Surgery Followed by Spine Stereotactic Radiosurgery for Metastatic Epidural Spinal Cord Compression
Favorite
NCOG-05
Management of Brain Metastasis in Triple Negative Breast Cancer
Favorite
NCOG-07
Features of Epileptogenic Brain Metastases and Their Treatment
Favorite
NCOG-08
A comparison of response-assessment and data visualization methods for characterization of time-dependent outcomes following radiosurgery (SRS) for brain metastases
Favorite
NCOG-10
ASSESSMENT OF SURVIVAL AND SAFETY FOLLOWING INTRATHECAL CHEMOTHERAPY VIA OMMAYA RESERVOIR FOR LEPTOMENINGEAL DISEASE
Favorite
NCOG-11
Post-radiosurgical outcomes of cystic vestibular schwannomas, a systematic review and meta-analysis
Favorite
NCOG-12
Stereotactic Radiosurgery for Vestibular Schwannomas in Neurofibromatosis type 2 Patients: a Systematic Review and Meta-Analysis
Favorite
NCOG-13
The impact of CME on the knowledge of neurofibromatosis type 1-related tumors
Favorite
NCOG-14
Psychosocial Outcomes in Children with Neurofibromatosis Type 1 and Plexiform Neurofibromas
Favorite
NCOG-15
Pregnancy and glioma
Favorite
NCOG-17
Predictors of survival in elderly patients undergoing surgery for GBM
Favorite
NCOG-19
Bevacizumab in real life patients with recurrent glioblastoma: benefit or futility?
Favorite
NCOG-20
Awake surgery for right frontal lobe glioma can improve the resection rate and preserve higher cognitive functions
Favorite
NCOG-21
Interim results of three cognitive rehabilitation strategies in patients with lower grade gliomas
Favorite
NCOG-23
Patterns of distress in older patients with glioblastoma: a follow-up to a single institution cross-sectional study of distress in primary brain tumor patients.
Favorite
NCOG-24
Wake Forest NCORP Research Base feasibility study of ramipril for preventing cognitive decline in glioblastoma patients receiving brain radiotherapy (WF-1801)
Favorite
NCOG-25
Efficacy of anticonvulsant therapy in glioma patients
Favorite
NCOG-26
Impact of Gender on Tumor Treating Fields Compliance in Patients with Glioblastoma
Favorite
NCOG-28
Surgery for recurrent GBM improves survival independent of prognostic factors
Favorite
NCOG-29
O
6
-methylguanine DNA methyltransferase (MGMT) promoter methylation status and the incidence of temozolomide-induced hematologic toxicity: an association study
Favorite
NCOG-30
Adjuvant versus Salvage Management for IDH-mutant Low Grade Glioma
Favorite
NCOG-33
Hematologic Predictors of Outcomes in Glioblastoma treated with Surgery and Chemoradiation
Favorite
NCOG-34
An assessment of overall survival and palliative care use among patients with gliosarcoma diagnosed over a twelve-year span
Favorite
NCOG-35
Predictors of Postoperative Seizures in Patients with Glioblastoma Multiforme
Favorite
NCOG-36
FIRST HEALTH UTILITIES OF GLIOBLASTOMA PATIENTS USING TTFIELDS TREATMENT
Favorite
NCOG-37
Natural language assessment correlates with health-related quality of life in adult glioma patients
Favorite
NCOG-39
Progression-Free and Survival Rate of Chemotherapy in Pediatrics with Optic Pathway Gliomas: A Systematic Review
Favorite
NCOG-40
Implementing RANO criteria in a resource-limited setting and its association with overall survival of glioma patients: Experience from a National Cancer Center in Indonesia
Favorite
NCOG-41
Functional outcome following non-dominant hemispheric glioma surgery from the aspect of independence level, cognitive function and return to social lives
Favorite
NCOG-42
Initial presentation and outpatient visit compliance of inmates with brain tumors.
Favorite
NCOG-43
Neurocognitive impairment and frailty in geriatric patients with high grade glioma and thoracic malignancy
Favorite
NCOG-44
Neurologic Assessment in Neuro-Oncology (NANO) scale in a phase II study of pembrolizumab or pembrolizumab plus bevacizumab in patients with recurrent glioblastoma.
Favorite
NCOG-46
A pilot study of germline coding mutations associated with impaired development and adaptive behavior in pediatric medulloblastoma patients treated on Head Start 4
Favorite
NCOG-48
Transformation from low grade meningioma and prognostic factors for shorter time to recurrence of WHO grade III meningioma diagnosis
Favorite
NCOG-51
Correlation between tumor volume and serum prolactin and impact of tumor cellular density on prolactinoma surgical outcomes in a cohort of 181 patients
Favorite
NCOG-52
Tumor Treating Fields in Meningioma
Favorite
NCOG-54
Safety of transsphenoidal surgery for nonfunctioning pituitary adenoma in elderly patients
Favorite
NCOG-55
Harmonizing language to maximize impact: an update on common data elements for meningioma and review of clinical trials in meningioma
Favorite
NCOG-57
Neuropsychological Function in Meningeal Melanocytoma: A Case Report
Favorite
NCOG-58
Impact of time from presentation to treatment initiation on clinical outcomes in central nervous system lymphoma
Favorite
NCOG-59
Progression-free survival as a primary outcome measure to compare consolidative strategies in relapsed/refractory primary CNS lymphoma.
Favorite
NCOG-60
Malignant melanoma in neurocutaneous melanocytosis: a retrospective case series (2000-2020)
Favorite
NCOG-61
A case of long term survivor of disseminated and relapsed germinoma.
Eighteen years of follow up
Favorite
NCOG-62
CNS sarcoma in a toddler with novel balanced translocation of t(8;11)(q13;q13).
Favorite
NCOG-64
Incidence of early ocular complications after proton radiation for childhood brain tumors
Favorite
NCOG-66
Implication of D-Dimer in the detection of Deep Venous Thrombosis( DVT) /Pulmonary Embolism(PE) in High grade Glioma patients with out classic symptoms of DVT/PE on or off Avastin treatment.
Favorite
NCOG-68
Comparing cognitive profiles of persons with brain and non-brain metastatic cancer
Favorite
NCOG-69
Sex differences in glioblastoma patient survival as a function of extent of surgical resection and cycles of adjuvant temozolomide during standard-of-care regimens
Favorite
NCOG-71
Genome associations with neurocognitive outcomes, cerebral microbleeds (CMBs), and brain volume and white matter (WM) changes in pediatric brain tumor survivors
Favorite
NCOG-72
Differential effects of surgery and chemotherapy on children with posterior fossa brain tumors
Favorite
NCOG-73
Effect of time to diagnosis in children with malignant central nervous system tumors on survival outcomes and disease-associated morbidity: an institutional cohort study
Favorite
NCOG-75
Estimated physician cost of a neuro-oncology multidisciplinary team (MDT) tumor board meeting at a single academic center.
Favorite
NCOG-76
Baseline cognitive assessment in glioma patients with MGMT promotor methylation and/or 1p19q codeletion
Favorite
NIMG-01
MRI Virtual Biopsy and Treatment of Primary or Brain Metastatic Tumors with Targeted Nanobioconjugates
Favorite
NIMG-02
18
F-Fluciclovine PET/CT to Distinguish Radiation Necrosis from Tumor Progression in Brain Metastases Treated with Stereotactic Radiosurgery
Favorite
NIMG-04
MRI evaluation of the effect of whole brain radiotherapy on brain metastasis
Favorite
NIMG-05
Advanced imaging to assess longitudinal vascular changes in brain metastases treated with checkpoint inhibition
Favorite
NIMG-06
Guillain Barre mimicking leptomeningeal spread in cancer patients: report of two cases an review of literature
Favorite
NIMG-07
Long-term follow-up of schwannoma growth behavior in adult neurofibromatosis type 2 and schwannomatosis patients using whole-body MRI
Favorite
NIMG-09
Predicting overall survival of glioblastoma patients on multi-institutional histopathology stained slides using deep learning and population-based normalization
Favorite
NIMG-10
A retrospective analysis of survival following treatment with bevacizumab in glioblastoma patients with radiographically-confirmed subependymal or leptomeningeal spread of disease
Favorite
NIMG-11
Impact of inversion time for FLAIR acquisition on the T2-FLAIR mismatch detectability for IDH-mutant, non-CODEL astrocytomas
Favorite
NIMG-12
18F-fluorethyltyrosine positron emission tomography versus magnetic resonance spectroscopy in preoperative detection of newly diagnosed gliomas by using machine learning
Favorite
NIMG-14
Machine learning-based evaluation of static and dynamic FET-PET for the detection of pseudoprogression in patients with IDH-wildtype glioblastoma
Favorite
NIMG-15
Evaluating fluctuating enhancement in oligodendrogliomas on magnetic resonance imaging
Favorite
NIMG-16
Exploratory evaluation of q-space trajectory imaging parameters as novel imaging biomarkers for gliomas
Favorite
NIMG-17
Validation of diffusion MRI as an imaging biomarker for bevacizumab therapy in recurrent glioblastoma in a randomized phase III trial of bevacizumab with or without VB-111 (GLOBE)
Favorite
NIMG-18
The clinical significance of
13
N-NH
3
,
18
F-DOPA, and
18
F-FDG PET/CT in the differential diagnosis between glioma recurrence and treatment effects
Favorite
NIMG-19
Using functional Ultrasound (fUS) to map brain functionality and tumor vasculature with micrometer-millisecond precision
Favorite
NIMG-22
Integration of a Radiomic Signature, Clinical variables and Plasma Cell-free DNA in Adult Patients with Newly Diagnosed
Glioblastoma Predicts Patient Survival and Improves Disease Stratification
Favorite
NIMG-23
Comparison of a radio-pathomic model versus a radiology-only tumor segmentation model for the detection of infiltrative tumor in glioma patients
Favorite
NIMG-24
Glycine and glutamine by MR spectroscopy are imaging biomarkers of glioma aggressiveness
Favorite
NIMG-25
Transferrin Receptor 1 Targeted PET/CT and NIFR Probes for Imaging Glioblastoma mouse Models
Favorite
NIMG-26
Diagnosis of pseudoprogression following radiotherapy plus lomustine-temozolomide chemotherapy in newly diagnosed glioblastoma patients using FET PET
Favorite
NIMG-27
Threshold values of early metabolic changes in 1H MRSI metabolic metrics predictive for survival in patients with newly diagnosed high-grade glioma
Favorite
NIMG-29
Developing
automatic segmentation method for brain tumor MR images that can be used at multiple facilities
Favorite
NIMG-30
PET IMAGING OF ANDROGEN RECEPTOR EXPRESSION IN PATIENTS WITH GBM USING [
18
F]-FDHT
Favorite
NIMG-31
Non-DIPG Patients Enrolled in the International DIPG Registry: Histopathologic Evaluation of Central Neuro-Imaging Review
Favorite
NIMG-32
The predictive capacity of pre-operative imaging analysis in diffuse glioma: A comparison of connectomics, radiomics, and clinical predictive models
Favorite
NIMG-33
Changes in magnetic resonance imaging after proton boost therapy for glioblastoma with and without Tumor Treating Fields therapy
Favorite
NIMG-34
Quantitative MR Parameters for the Prediction of EGFR Amplification and the TERT Promoter Mutation Status of IDH-Wildtype Lower-grade Gliomas
Favorite
NIMG-35
Improving CETCS microneedle visibility in a magnetic resonance imaging environment
Favorite
NIMG-36
Automatic stratification of enhancing and non-enhancing gliomas into genetic subtypes using deep neural networks and diffusion-weighted imaging
Favorite
NIMG-37
Delayed pseudoprogression in two patients undergoing TTFields treatment for newly diagnosed glioblastoma
Favorite
NIMG-38
Non-invasive prediction of MGMT promoter methylation using combined FET PET/MRI radiomics
Favorite
NIMG-39
Utility of Physiologic MR Metrics in Distinguishing True-progression from Pseudoprogression in Glioblastomas Stratified by MGMT Promoter Methylation
Favorite
NIMG-41
Variation in perfusion and permeability MRI depending on vascular input function selection
Favorite
NIMG-42
Horos Software for Postoperative Analysis of Pediatric High-Grade Gliomas
Favorite
NIMG-43
Imaging findings following regorafenib in patients with malignant glioma: FET PET adds valuable information to anatomical MRI
Favorite
NIMG-44
Integrating automated lesion segmentations from single-images into routine clinical workflow for volumetric response assessment
Favorite
NIMG-46
Radiogenomic features predict clinically relevant genome-wide alteration signatures in glioblastoma
Favorite
NIMG-47
Metabolic characterization of IDH mutant lower grade glioma using spectroscopic imaging optimized for 2-hydroxyglutarate detection
Favorite
NIMG-50
Initial experience: detection of aberrant hyperpolarized [1-
13
C]pyruvate metabolism in patients with GBM prior to resection
Favorite
NIMG-52
Characterization of Cognitive Function in Survivors of Diffuse Gliomas using Morphometric Correlation Networks (MCN)
Favorite
NIMG-53
Glutamate/GABA ratio on MRS is elevated in patients with lower grade gliomas and seizures
Favorite
NIMG-54
Diffuse tumor growth pattern is associated with worse outcome only in
IDH
wildtype but not in
IDH
mutant gliomas WHO II and III
Favorite
NIMG-55
A quantitative analysis of brain volume dynamics in PCNSL patients treated with high-dose methotrexate-based therapy
Favorite
NIMG-56
The Rare Case of Primary Dural Based Marginal Zone B-Cell Lymphoma Camouflaging as Mild Focal Dura Thickness and Pacymeningeal Enhancement
Favorite
NIMG-57
Association of Radiomics Based Tumor Shape Irregularity Measures and Gamma Knife Dose Planning Indices in Vestibular Schwannomas
Favorite
NIMG-58
The effect of cell confluence on the distribution of Tumor Treating Fields
Favorite
NIMG-60
Atypical posterior reversible leukoencephalopathy syndrome mimicking tumor in 1
st
trimester pregnancy-
'Don't believe everything you see'
Favorite
NIMG-61
Unusual Presentation of Neurosarcoidosis: a Case Series
Favorite
NIMG-62
Amphetamine-associated CNS vasculitis masquerading as tumour
Favorite
NIMG-63
The application of MRI and treatment response assessment maps (TRAMs) for monitoring treatment effects during/following proton beam therapy – initial experience
Favorite
NIMG-64
DISTINCT IMAGING PATTERNS OF PSEUDOPROGRESSION IN GLIOMA PATIENTS FOLLOWING PROTON VERSUS PHOTON RADIATION THERAPY
Favorite
NIMG-65
Study of local perturbation in computational modelling on Tumor Treating Fields (TTFields) therapy
Favorite
NIMG-66
AI-based Prognostic Imaging Biomarkers for Precision Neurooncology and the ReSPOND Consortium
Favorite
NIMG-67
Disappearing Dots – Transient Late Enhancing Lesions Years After Brain Radiotherapy
Favorite
NIMG-68
Mathematical Modeling of Thermal Damage Estimate Volumes in Magnetic Resonance-guided Laser Interstitial Thermal Therapy
Favorite
NIMG-69
Personalized Connectomic Signatures: Bridging the Gap Between Neuro-Oncology and Connectomics
Favorite
PATH-01
Brain metastases from endometrial carcinoma: tumor genetic alterations in a case series and meta-analysis
Favorite
PATH-02
Characterization of Functional Network Effects in the Cerebral Cortex During Brain Tumorigenesis in the Mouse
Favorite
PATH-04
The blood-brain barrier in diffuse midline glioma and its implications for drug delivery
Favorite
PATH-05
A retrospective study of treatment strategies and outcomes in WHO grade II and III isocitrate dehydrogenase
(IDH)
wild-type astrocytoma
Favorite
PATH-07
Significance of H3K4me3 in pediatric high-grade gliomas
Favorite
PATH-08
Evaluation of Mismatch Repair Gene Expression by Immunohistochemistry May Detect Early Phase of MMR deficiency in Recurrent Gliomas.
Favorite
PATH-08
Evaluation of Mismatch Repair Gene Expression by Immunohistochemistry May Detect Early Phase of MMR deficiency in Recurrent Gliomas
Favorite
PATH-10
Effects of 19q-loss in
IDH
-mutated astrocytomas on better prognosis and oligodendroglioma-like morphology
Favorite
PATH-16
Comprehensive genomic profiling accurately determines 1p19q codeletion status in gliomas
Favorite
PATH-17
Novel Dual Histone 3 K27M and G34R Point Mutations in a Midline Glioma
Favorite
PATH-18
A multi-center case series of adult K27M mutated diffuse midline gliomas revealing a population unique from paediatric cases.
Favorite
PATH-19
Molecular, Histologic and Clinical Characteristics of Oligodendrogliomas: A Multi-institutional Retrospective Study
Favorite
PATH-24
Detection of point mutations and gene fusions from circulating cell-free DNA (cfDNA) of glioblastoma (GBM) patients
Favorite
PATH-27
Clinical, Radiologic and Prognostic Profile of IDH wild type Diffuse Astrocytoma with Molecular Features of Glioblastoma.
Favorite
PATH-28
Extent and prognostic value of MGMT promotor methylation depend on IDH mutation and 1p19q co-deletion in glioma WHO grade II
Favorite
PATH-29
Comparative analysis of DNA methylation profiles associated with IDH-wildtype glioma and glioneuronal tumor subtypes.
Favorite
PATH-30
Clinical and Genetic Characteristics of Histone H3 K27M-mutant Diffuse Midline Gliomas in Adults
Favorite
PATH-34
Genetic profiling of aggressive meningiomas reveal diverse spectrum of accompanying alterations beyond
NF2
inactivation
Favorite
PATH-36
Synchronous TTF-1-Positive tumors and pituitary adenomas. Are we sending insufficient tumor tissue for pathology?
Favorite
PATH-37
Identifying High-Risk Patients for WHO Grade I Meningioma Recurrence Using Histopathological Features and the MIB-1 Index
Favorite
PATH-38
Metastatic Meningioma Causing Chronic Respiratory Failure
Favorite
PATH-40
Intragenic
DMD
deletions are the most common recurrent genomic alterations in esthesioneuroblastoma
Favorite
PATH-42
Combined next generation sequencing and Immunohistochemistry in the differential diagnosis of a progressive neuronal-glial tumor: a composite neoplasm
Favorite
PATH-43
Targeted genomic analysis of primary adult brain tumors: A single institutional experience of 26 cases
Favorite
PATH-44
An Unusual Presentation of a Pediatric Midline H3K27M-Mutant Tumor with Disseminated Craniospinal Leptomeningeal Disease
Favorite
QOLP-01
Outcome Assessment Of Multidisciplinary Brain Tumor Board Meeting Recommendations For Brain Metastasis: Is There A Gap?
Favorite
QOLP-03
Neuro-oncology palliative care survey of physicians in Sub-Saharan Africa
Favorite
QOLP-04
Pilot Study of a Videoconference-Based Psychological Intervention for Family Caregivers of Patients with Malignant Gliomas
Favorite
QOLP-05
Olanzapine for Refractory Chemotherapy-Induced Nausea and Vomiting in Malignant Glioma Patients
Favorite
QOLP-06
Phenomenological exploration of the lived experience of quality of life for patients with glioblastoma and their primary care partners
Favorite
QOLP-07
Health-related quality of life and symptom burden in patients with newly diagnosed glioblastoma treated with bevacizumab beyond progression: a prospective trial
Favorite
QOLP-08
Utilizing stakeholder engagement to develop a mindfulness-based intervention for patients with Glioblastoma (GBM) and their caregivers
Favorite
QOLP-09
Health economic evaluation of low-grade glioma management: a systematic review
Favorite
QOLP-10
Monitoring trends in patient distress in glioblastoma using the PHQ4 questionnaire
Favorite
QOLP-11
Quality of End-of-Life Care in Patients with High Grade Gliomas
Favorite
QOLP-13
Comparison of symptom burden and associated impact on daily life in glioblastoma patients treated with and without Tumor Treating Fields
Favorite
QOLP-14
From symptoms to radiotherapy: a qualitative assessment of patient experience in newly diagnosed high-grade glioma
Favorite
QOLP-16
Efficacy of Scrambler Therapy (Calmare®) For the Treatment of Chronic Chemotherapy-induced Peripheral Neuropathy
Favorite
QOLP-19
Insomnia in brain tumor patients: Assessing needs in neuro-oncology
Favorite
QOLP-20
A feasibility study utilizing mindfulness meditation during concomitant chemoradiation in malignant glioma patients: health-reported quality of life (HRQoL) results
Favorite
QOLP-21
A Preliminary Report on Quality of Life and Sexual Function in Brain Cancer Patients
Favorite
QOLP-23
Phase II randomised placebo-controlled double-blind study of acetazolamide versus placebo for cerebral oedema in recurrent and/or progressive high-grade glioma requiring treatment with dexamethasone
Favorite
QOLP-24
Engaging Patients and Caregivers to Improve the Importance and Quality of Supportive Care Research in Neuro-Oncology
Favorite
QOLP-25
Baseline quality of life burden in patients with central nervous system (CNS) tumours treated with pencil beam proton therapy at India’s first proton therapy centre
Favorite
QOLP-27
Use of the Neuro-QOL Cognitive Function Short-Form as a Tool for Assessing Patient-Perceived Neurocognition Following Radiotherapy
Favorite
QOLP-28
Preoperative sleep disturbance and its association with quality of life in adult brain tumor patients
Favorite
QOLP-29
Information on headache for brain tumor patients on internet –guiding or misleading?
Favorite
QOLP-30
Fear of Cancer Recurrence in Primary Brain Tumor Patients: Do Disease-Related Characteristics Matter?
Favorite
RADT-01
The efficacy and safety of two-staged stereotactic radiosurgery for large posterior fossa metastases: post-treatment volumetric changes in tumor size, peri-tumoral edema, and fourth ventricle
Favorite
RADT-04
Resection cavity failure of melanoma brain metastases when treated with systemic therapy, with or without focal radiotherapy.
Favorite
RADT-05
Clinical Outcomes of Proton Craniospinal Irradiation for Patients with Leptomeningeal Carcinomatosis
Favorite
RADT-06
Volume kinetics following two-session Gamma Knife radiosurgery for large brain metastases (BM)
Favorite
RADT-07
Stereotactic radiosurgery of patients with brain metastases and poor prognosis.
Favorite
RADT-09
Type and timing of systemic therapy use predict survival in patients with brain metastases treated with radiation therapy
Favorite
RADT-10
Survival in Patients fulfilling CCTG CE.7 Eligibility Criteria: Evaluating Initial Stereotactic Radiosurgery for 5-15 Brain Metastases
Favorite
RADT-12
Disease Characteristics in Acute Seizure following Radiotherapy for Brain Metastases
Favorite
RADT-14
Comparison of machine learning algorithms in distinguishing radiation necrosis from progression of brain metastases treated with stereotactic radiosurgery (SRS)
Favorite
RADT-16
Hypofractionated Radiotherapy and Stereotactic Radiosurgery for Vestibular Schwannomas: a Systematic Review and Meta-Analysis
Favorite
RADT-18
Long-term follow-up of patients treated with Gamma Knife® stereotactic radiosurgery (GK-SRS) for vestibular schwannoma (VS)
Favorite
RADT-19
Effects of radiation dose-rate and tumor characteristics on local control and toxicity after radiosurgery for acoustic neuromas
Favorite
RADT-20
Histopathologic findings in malignant peripheral nerve sheath tumor are both prognostic for overall survival and predictive for response to radiation therapy
Favorite
RADT-21
National Practice Patterns and Outcomes of Stereotactic Body Radiotherapy vs. Conventional External Beam Radiotherapy for Spinal Metastases
Favorite
RADT-23
Impact of Reirradiation Utilizing Stereotactic Radiosurgery on Recurrent Glioblastoma
Favorite
RADT-24
High absorbed doses of Rhenium-186 nanoliposomes (RNL) in recurrent GBM: a phase 1 study
Favorite
RADT-25
Evaluating lymphocyte counts in newly diagnosed glioblastoma patients receiving chemoradiation
Favorite
RADT-26
Laser Interstitial Thermal Therapy for Recurrent Glioblastoma: Pooled Analyses of Available Literature
Favorite
RADT-28
Radiation dose-dependent long-term neurocognitive decline in low grade glioma patients: results of a cross-sectional study
Favorite
RADT-31
Patterns of care in the use of adjuvant radiotherapy and chemotherapy in low grade glioma patients in the United States from 2010-2016
Favorite
RADT-33
Radiosurgery versus combination radiosurgery-bevacizumab for the treatment of recurrent high-grade glioma: a systematic review
Favorite
RADT-36
Prospectively Assessed Tumor Control and Toxicity of Benign Intracranial Pathologies Treated with Automated VMAT Radiosurgery – Initial 2 Year Experience with First 100 Patients
Favorite
RADT-37
The Impact of Postoperative Radiation Therapy (PORT) And Extent of Surgery on Clinical Outcomes of Atypical Meningioma (AM): A Meta-Analysis
Favorite
RADT-38
Adjuvant radiotherapy for intracranial atypical and malignant Meningiomas in adult patients
Favorite
RADT-39
68Ga- DOTATATE CT/PET for Gamma Knife Radiosurgery Planning and Target Delineation in Patients with Meningioma
Favorite
RADT-40
Trends in the use of radiation for meningioma across the United States
Favorite
RADT-41
Assessing the role of adjuvant radiation therapy and risk factors for recurrence following gross total resection of atypical meningiomas
Favorite
RADT-42
Adjuvant Radiation Therapy for Subtotally Resected Cerebellar Liponeurocytoma
Favorite
RADT-43
Treatment of Retroperitoneal Leiomyosarcoma Brain Metastases with Stereotactic Radiosurgery
Favorite
RADT-46
Systematic review of radiosensitizers for malignant brain tumors: potential for learning from past failures
Favorite
RADT-47
A multicenter observational study of surgically targeted radiation therapy (STaRT) using implanted Cs-131 seeds in a collagen-based carrier tile in intracranial brain neoplasms - protocol in progress
Favorite
RBIO-03
Heterogeneity of human patient-derived xenografts growth rates responses to the radiated microenvironment
Favorite
RBIO-04
New Therapeutic Delivery Methods for Tumor-Treating Fields for Higher Efficacy
Favorite
RBIO-06
Implementation of human induced pluripotent stem cell derived cerebral organoids to model normal tissue radioresponse
Favorite
RTID-01
Radiosurgery followed by Tumor Treating Fields for brain metastases (1-10) from NSCLC in the phase 3 METIS trial
Favorite
RTID-03
A Phase I Clinical Trial to Evaluate MTD of Perampanel and Memantine in Combination with Standard Chemoradiotherapy for the Treatment of Patients With Newly Diagnosed GBM –A Study Design
Favorite
RTID-04
A randomized phase II trial to compare the efficacy of standard versus combination therapy (Perampanel, Memantine plus standard) in the treatment of patients with newly diagnosed GBM-A Study Design
Favorite
RTID-05
INDIGO: A global, randomized, double-blind, phase 3 study of vorasidenib (AG-881) vs placebo in patients with residual/recurrent grade II glioma with an isocitrate dehydrogenase 1/2 (
IDH1/2
) mutation
Favorite
RTID-06
Enhancing Tumor Treating Fields therapy for recurrent glioblastoma with targeted and individualized skull remodeling surgery. A multi-center randomized phase 2 trial
Favorite
RTID-07
Human Placental hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) for Treatment of Recurrent Glioblastoma
Favorite
RTID-08
A Phase 1/2 study of Selinexor in combination with standard of care therapy for newly diagnosed or recurrent Glioblastoma (ndGBM or rGBM)
Favorite
RTID-09
A Randomized, Double-Blinded, Phase 3 Study of Enzastaurin Added to Temozolomide During and Following Radiation Therapy in Newly Diagnosed Glioblastoma Patients Who Possess the Novel Biomarker, DGM1
Favorite
RTID-10
Surgeons Trial Of Prophylaxis for Epilepsy in seizure naïve patients with Meningioma: a randomized controlled trial (STOP ‘EM)
Favorite
RTID-11
GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma
Favorite
RTID-12
Phase 2 trial of Tumor Treating Fields (TTFields) plus radiation therapy (RT) plus temozolamide (TMZ) compared to RT plus temozolomide in newly diagnosed glioblastoma (ndGBM)
Favorite
STEM-02
In vivo phage display identifies peptide targeting N-cadherin on glioma stem cells
Favorite
STEM-03
WAVE1 Knockdown Enhances the Antitumor Efficacy in Primary Glioblastoma Neurospheres
Favorite
STEM-04
Platelets Drive Glioblastoma Oncogenesis by Enhancing the Glioma Stem Cell Phenotype
Favorite
STEM-05
Single Cell Sequencing Characterizes Spatial and Temporal Relationships of Enhancing and Non-Enhancing Regions in High-Grade Glioma
Favorite
STEM-06
The role of IFITMs in maintaining glioma stem cells
Favorite
STEM-08
Platelets drives glioblastoma oncogenesis by enhancing the glioma stem cell phenotype
Favorite
STEM-09
Intrinsic interferon signaling regulates the cell death of glioblastoma stem cells
Favorite
STEM-10
Long-lasting Tumor Treating Fields (TTFields) stimulation of glioblastoma primary culture damages preferentially fully differentiated cancer cells
Favorite
STEM-11
Interrogating intratumoral transcriptomic heterogeneity and plasticity as resistance mechanisms in Glioblastoma
Favorite
STEM-13
Functional characterization of the ZFHX4-CHD4 interaction in glioblastoma cancer stem cells
Favorite
STEM-14
Glioblastoma stem cell targeting chimeric antigen receptor T cells modified using phage display isolated peptides
Favorite
STEM-15
Small but Fierce: The Role of Extracellular Vesicles in Mesenchymal Transition and Therapeutic Resistance in Glioblastoma
Favorite
STEM-17
Not all GBM stem cells are equal: implications for research and therapy
Favorite
STEM-19
The isolation and identification of Glioma Stem Cells and Mesenchymal Stem Cells From Human Glioma Specimens
Favorite
STEM-20
A Cancer Stem Cell-Selective Apoptosis-Inducing Small Molecule For The Treatment Of GBM
Favorite
STEM-21
Clinical relevance of cancer stem cell cytotoxicity assay in guiding treatment for glioblastoma
Favorite
STEM-22
Targeting KIF11 to Radiosensitize Glioblastoma
Favorite
STEM-23
Inhibiting protein phosphatase 2A increases the antitumor effect of protein arginine methyltransferase 5 inhibition in models of glioblastoma
Favorite
STEM-24
Radiation-induced extracellular vesicle (EV) release of miR-603 promotes IGF1-mediated stem call state in glioblastomas
Favorite
STEM-25
Differential regulation of glioma stem-cell marker nestin and CD24 in IDH-mutant glioma
Favorite
STEM-26
Small molecule drug CBL0137 inhibits the FACT complex and sensitizes glioblastoma cancer stem cells to radiotherapy
Favorite
STEM-27
miR-10b-5p modulates 5hmC expression and the stem-like phenotype in GBM
Favorite
SURG-04
Salvage resection of recurrent previously-irradiated brain metastases: clinical and radiographic outcomes
Favorite
SURG-05
Ideal treatment regimen for patients with ≥1 brain metastasis from primary non-small-cell lung cancer – a systematic review and network meta-analysis
Favorite
SURG-06
Management of hydrocephalus in adult patients with brain metastases
Favorite
SURG-08
Awake craniotomy with brain mapping for diffuse low-grade glioma: case report of institutional experience in overcoming hurdles in a low-resource setting
Favorite
SURG-10
Prognostic importance of the extent of resection in IDH-wild type grade II astrocytomas according to pTERT mutation.
Favorite
SURG-11
Neoadjuvant chemotherapy for diffuse gliomas: A feasible option?
Favorite
SURG-12
Predictors of survival and utility of intraoperative MRI for resection of grade II astrocytomas and oligodendrogliomas: a multicenter analysis
Favorite
SURG-15
A novel risk model to define the relative benefit of maximal extent of resection within prognostic groups in newly diagnosed diffuse low-grade glioma
Favorite
SURG-16
Predictors of Local Control Following Laser Interstitial Thermal Therapy for Glial Tumors.
Favorite
SURG-19
Evaluation of Serum Neuron Specific Enolase, Interferon-alpha, and Interferon-gamma in Response to Laser Ablation of High Grade Gliomas
Favorite
SURG-23
Reoperation in Molecular Subtypes of Recurrent Glioblastoma
Favorite
SURG-24
Repeat Convection-Enhanced Delivery for Diffuse Intrinsic Pontine Glioma
Favorite
SURG-27
Treating Hydrocephalus in Diffuse Midline Gliomas with an H3 K27M Mutation
Favorite
SURG-28
Presentation of a posterior fossa tumor at a hospital in western Jamaica
Favorite
SURG-29
Clinical factors associated with recurrence in atypical meningioma: retrospective analysis of 99 patients in two institutes
Favorite
SURG-31
Surgical Outcome Analyses on 244 Central Nervous System Hemangioblastoma
Favorite
SURG-32
Differences in surgical outcome between von Hippel-Lindau disease related and sporadic hemangioblastomas in the central nervous system
Favorite
SURG-33
Role of Surgery in Treating Epstein-Barr Virus-Associated Smooth Muscle Tumor (EBV-SMT) with Central Nervous System Invasion: A Systemic Review
Favorite
SURG-34
Multidisciplinary management of a patient with optic pathway-hypothalamic langerhans cell histiocytosis: a case report
Favorite
SURG-35
Intracranial myxoid mesenchymal tumor with EWSR1-ATF1 gene fusion
Favorite
SURG-37
Systematic review of Gamma-knife Radiosurgery and Microsurgical Resection for Brainstem Cavernous Malformations.
Favorite
SURG-38
Seizure outcome after epilepsy surgery in children with brain tumors
Favorite
SURG-40
Surgical resections in Broca’s Area do not lead to Broca’s aphasia
Favorite
SURG-41
Blood-brain barrier disruption with high-frequency electroporation in vivo: a preliminary investigation demonstrating the effects of varied pulse widths and intra-phase delays
Favorite
SURG-43
Applications and restriction of 980nm diode laser for brain tumor microsurgery - a pioneer case series and a critical review
Favorite
TAMI-02
Alterations in C-X3-C motif chemokine receptor 1 (CX3CR1) expression influence microglial and macrophage response in different steps of cerebral metastasis formation
Favorite
TAMI-03
Identification of novel drivers of lung-to-brain metastasis through
in vivo
functional genomics
Favorite
TAMI-04
Tumor Treating Fields (TTFields) hinder glioma cell motility through regulation of microtubule and actin dynamics
Favorite
TAMI-06
Preclinical models reveal brain-microenvironment specific metabolic dependencies in glioblastoma
Favorite
TAMI-09
Energy metabolism and therapeutic T cell efficacy in the glioblastoma microenvironment
Favorite
TAMI-10
Circulating angiogenic cells (CACs) in glioblastoma: towards defining crucial functional differences in CAC-induced neoplastic versus reactive neovascularization
Favorite
TAMI-11
Impact of oHSV activated NOTCH signaling in tumor microenvironment, and its impact on anti-tumor immunity
Favorite
TAMI-14
Nanoparticle delivery of PD-L1 CRISPR/Cas9 plasmid DNA for anti-Glioblastoma immunotherapy
Favorite
TAMI-15
The effect of interstitial fluid flow and astrocytes / microglia on invasion, proliferation and stemness of patient-derived glioma stem cells
Favorite
TAMI-16
Biomaterial matrices to study glioblastoma invasion
Favorite
TAMI-17
Relationship between iron metabolism, immune cell infiltration and sex-based survival differences in gliomas
Favorite
TAMI-18
Single-cell sequencing and genetic labeling to characterize hypoxic GBM cells in their microenvironment
Favorite
TAMI-22
Variation among intact tissue samples reveals the core transcriptional identities of cell types in the glioma microenvironment
Favorite
TAMI-23
Neutrophil-triggered ferroptosis promotes tumor necrosis in glioblastoma progression
Favorite
TAMI-24
Behavior of glioblastoma stem-like cells with known
IDH1
status in cerebral organoids
Favorite
TAMI-29
Multifactorial upregulation of ID1 drives DIPG invasiveness and is therapeutically targetable
Favorite
TAMI-34
Sex-specific metabolic adaptations to the ketogenic diet in a mouse model of glioblastoma
Favorite
TAMI-36
Connexin 43 blockade inhibits proliferation in IDH1-mutant glioma cells
Favorite
TAMI-38
Cysteine-promoting compounds induce mitochondrial toxicity in glioblastoma through altered pyruvate and serine metabolism
Favorite
TAMI-39
Age-dependent phenotypic conversion from neuronal activity to neuro-inflammation in glioblastoma progression
Favorite
TAMI-40
Tumor microbiome and Glioblastoma (GBM)
Favorite
TAMI-43
Impact of sex and radiation on iron trafficking in bone marrow derived macrophages
Favorite
TAMI-45
Phenogenomic characterization of immunomodulatory purinergic signaling in glioblastoma
Favorite
TAMI-47
Evaluation of the effect of microenvironmental stresses on glioma stemness
in vitro
and
ex vivo
.
Favorite
TAMI-48
Engraftment phenotypes in preclinical model systems reveal a functional subgroup of patient tumors dependent on the brain tumor microenvironment for growth
Favorite
TAMI-49
The Alternative Splicing Factor MBNL1 Inhibits Glioblastoma Tumor Initiation and Progression by Reducing Hypoxia-induced Stemness
Favorite
TAMI-50
Chitinase-3-like-1 protein binding complexes regulate immune suppression in glioblastoma
Favorite
TAMI-51
Identifying new Tumor Microenvironment (TME) contexts of vulnerability in Glioblastoma
Favorite
TAMI-54
The Presence of Immune Cell Infiltrates in the Tissue Microenvironment of High-Grade Gliomas and their Association with Overall Survival
Favorite
TAMI-55
The evolutionary enigma of fatty acid desaturation in Glioblastoma
Favorite
TAMI-58
A novel role for REST in the control of the medulloblastoma microenvironment
Favorite
TAMI-62
Angiogenesis inhibitors strongly synergize with therapeutics targeting tumor metabolism
Favorite
TAMI-63
Glioblastoma associated mesenchymal stem like cells (G-MSC) which infiltrate tumors in human and mouse are strongly associated with immunosuppression
Favorite
TAMI-64
Physical stresses in brain tumors
Favorite
TMOD-03
Pan-cancer analysis of orthotopic patient derived xenografts from brain metastases
Favorite
TMOD-05
Extracranial tumors influence intracranial response to immune checkpoint inhibitors in pre-clinical models of melanoma brain metastasis
Favorite
TMOD-06
Malignant transformation of plexiform neurofibromas in an Nf1 mutant mouse model of spinal irradiation
Favorite
TMOD-09
Glioblastoma biophysical growth estimation using deep learning-based regression
Favorite
TMOD-10
Effect of brain tumorigenesis on cerebral cortical functional connectivity in the mouse
Favorite
TMOD-12
Establishing a clinically relevant model of mesenchymal glioblastoma (GBM) to study response to standard of care treatment and immune checkpoint inhibition (ICI).
Favorite
TMOD-13
Research resources for oligodendroglioma now available to research community
Favorite
TMOD-14
Creation of a Genetically Engineered Mouse Model of Anaplastic Astrocytoma Driven by the
IDH1-R132H
Oncogene
Favorite
TMOD-15
Efficacy of the MDM2 inhibitor KRT-232 in glioblastoma patient-derived xenograft models
Favorite
TMOD-17
Oncolytic poliovirus as a probe for mechanisms of immune resistance in glioblastoma
Favorite
TMOD-18
Targeting the PI3K/Akt pathway in MYCN amplified high grade gliomas
Favorite
TMOD-20
A swine model of glioblastoma induced by somatic gene modification
Favorite
TMOD-24
Generation and characterization of a novel transgenic IDO reporter mouse for IDO posttranslational modification analysis
in situ
Favorite
TMOD-25
In vivo
model of treatment-resistant glioblastoma highlights sex differences in survival
Favorite
TMOD-26
Establishing a patient-derived, in-vitro organotypic slice culture model of GBM
Favorite
TMOD-27
Efficacy of soluble panobinostat (MTX110) in preclinical models of adult glioblastoma
Favorite
TMOD-29
Establishment of patient-derived xenografts from rare primary brain tumors
Favorite
TMOD-31
Novel Genetic Characterization of Murine Medulloblastoma Cell Lines
Favorite
TMOD-33
The Role of BAFF-R signaling in the growth of primary central nervous system lymphoma
Favorite
TMOD-37
In vivo compression and imaging for causal studies of mechanical forces in the brain
Favorite
Back to Top